
News|Articles|August 14, 2025
Early Experience of Aflibercept 8mg (EYLEA® 8mg) in Routine Clinical Practice
Advertisement
Sponsored Supplement:
One-to-one interviews with three leading retina specialists from Switzerland, United Kingdom and United States on their early experience of aflibercept 8mg (EYLEA® 8mg) in clinical practice, capturing contemporary insights on treatment strategies and real-world outcomes in patients with neovascular age-related macular degeneration and diabetic macular edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
2
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
3
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











